Search

OBJECTIVES: Although only 10% of persons infected with human T-lymphotropic virus type 1 (HTLV-1) may develop virus-associated illnesses over their lifetime, missing the earlier diagnosis of asymptomatic carriers frequently leads to late presentation. METHODS: A nationwide HTLV-1 register was created in Spain in 1989. We examined the main demographics and clinical features at the time of the first diagnosis for more than three decades. RESULTS: A total of 428 individuals infected with HTLV-1 had been reported in Spain until the end of 2021. Up to 96 (22%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (57%), T-cell lymphoma (34%), or Strongyloides stercoralis infestation (8%). Since 2008, HTLV-1 diagnosis has been made at blood banks (44%) or clinics (56%). Native Spaniards and Sub-Saharan Africans are overrepresented among patients presenting with HTLV-1-associated illnesses suggesting that poor epidemiological and/or clinical suspicion, which led to the late presentation are more frequent in them than carriers from Latin America (LATAM) (31.7% vs 20.4%, respectively; P = 0.015). CONCLUSION: HTLV-1 infection in Spain is frequently diagnosed in patients presenting with characteristic illnesses. Although screening in blood banks mostly identifies asymptomatic carriers from LATAM, a disproportionately high number of Spaniards and Africans are diagnosed too late at the time of clinical manifestations. Expanding testing to all pregnant women and clinics for sexually transmitted infections could help to unveil HTLV-1 asymptomatic carriers.

Background Despite most controlled trials have shown no measurable benefit of COVID-19 convalescent plasma (CCP) in patients with COVID-19, some studies suggest that early administration of CCP with high-titer anti-SARS-CoV-2 can be beneficial in selected patients. We investigated the efficacy of early administration of high-titer CCP to patients with COVID-19 who required hospitalization, Study design and methods Observational, propensity score (PS) matched case-control study of COVID-19 patients treated with CCP within 72 h of hospital admission and untreated controls from August 2020 to February 2021. All CCP donations had a Euroimmun anti-SARS-CoV-2 sample-to-cutoff ratio >= 3. PS matching was based on prognostic factors and presented features with high-standardized differences between the treated and control groups. The primary endpoint was mortality within 30 days of diagnosis. Results A total of 1604 patients were analyzed, 261 of whom received CCP, most (82%) within 24 h after admission. Median age was 67 years (interquartile range: 56-79), and 953 (60%) were men. Presenting factors independently associated with higher 30-day mortality were increased age, cardiac disease, hypoxemic respiratory failure, renal failure, and plasma d-dimer >700 ng/ml. After PS matching, transfusion of CCP was associated with a significant reduction in the 30-day mortality rate (odds ratio [OR]; 0.94, 95% confidence interval [CI]: 0.91-0.98; p = .001) that extended to the 60th day after COVID-19 diagnosis (OR: 0.95; 95% CI: 0.92-0.99; p = .01). Conclusion Our results suggest that CCP can still be helpful in selected patients with COVID-19 and call for further studies before withdrawing CCP from the COVID-19 therapeutic armamentarium.

Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor-recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain.

Consortia on behalf of the Spanish HTLV Network: C. Rodríguez, M. Vera, J. del Romero, G. Marcaida, M. D. Ocete, E. Caballero, I. Molina, A. Aguilera, J. J. Rodríguez-Calviño, D. Navarro, C. Rivero, M. D. Vilariño, R. Benito, S. Algarate, J. Gil, R. Ortiz de Lejarazu, S. Rojo, J. M. Eirós, A. San Miguel, C. Manzardo, J. M. Miró, J. García, I. Paz, E. Poveda, E. Calderón, D. Escudero, M. Trigo, J. Diz, M. García-Campello, M. Rodríguez Iglesias, A. Hernández Betancor, A. M. Martín, J. M. Ramos, A. Gimeno, F. Gutiérrez, J. C. Rodríguez, V. Sánchez, C. Gómez Hernando, G. Cilla, E. Pérez Trallero, J. López Aldeguer, L. Fernández Pereira, J. Niubó, M. Hernández, A. M. López Lirola, J. L. Gómez Sirvent, L. Force, C. Cifuentes, S. Pérez, L. Morano, C. Raya, A. González Praetorius, J. L. Pérez, M. Peñaranda, S. Hernáez Crespo, J. M. Montejo, L. Roc, A. Martínez Sapiña, I. Viciana, T. Cabezas, A. Lozano, J. M. Fernández, I. García-Bermejo, G. Gaspar, R. García, M. Górgolas, C. Vegas, J. Blas, P. Miralles, M. Valeiro, T. Aldamiz, N. Margall, C. Guardia, E. do Pico, I. Polo, A. Aguinaga, C. Ezpeleta, S. Sauleda, M. Pirón, R. González, L. Barea, A. Jiménez, L. Blanco, A. Suárez, I. Rodríguez Avial, A. Pérez Rivilla, P. Parra, M. Fernández, M. Fernández Alonso, A. Treviño, S. Requena, L. Benítez Gutiérrez, V. Cuervas Mons, C. de Mendoza, P. Barreiro, V. Soriano, O. Corral & F. Gómez-Gallego, [Background]: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide and severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1 associated illnesses due to immunosuppression, screening is being widely considered in the transplantation setting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organ transplants in a survey conducted in Spain., [Methods]: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLV antibody screening was performed retrospectively in all specimens collected from solid organ donors and recipients attended since the year 2008., [Results]: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312 (42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniards represented nearly 80%. Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients. Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another from Colombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developed within 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to be removed soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains in dialysis but otherwise asymptomatic., [Conclusion]: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants in Spain. Universal HTLV screening should be recommended in all donor and recipients of solid organ transplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk along with the rapid development of subacute myelopathy.

Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor–recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain.

Background. Although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. Methods. A nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. Results. A total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Strongyloides stercoralis infestation (n = 8; 14%). Human T-cell leukemia virus type 1 diagnosis had been made either at blood banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to note that Spaniards and especially Africans were overrepresented among patients presenting with HTLV-1-associated illnesses, suggesting that misdiagnosis and late presentation are more frequent in these populations compared to Latin Americans. Conclusions. Given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses.

Background: Human retroviruses HIV and HTLV share transmission routes. HIV widely spread in Spain during the 80 s through injection drug use and sex, and nowadays HIV rates in Spain account for one of the largest in Europe. In contrast, HTLV-1 is not endemic in Spain, despite hosting huge numbers of migrants from highly endemic regions. Herein, we report the rate and main features of the HIV-HTLV co-infected population in Spain. Methods: A national registry exists in Spain for HTLV since year 1989. Data from standardized case report forms and one centralized lab repository were reviewed, especially for the subset with HTLV-HIV co-infection. Results: Up to December 2018, a total of 369 individuals with HTLV-1 had been diagnosed in Spain. 64% of the population were females, and Latin American individuals accounted for 64.5%. Classical HTLV-associated illnesses were found in 12.7% (myelopathy) and 7.6% (leukemia). HIV coinfection was found in 12 (3.2%). Of those, 3 patients (25%) were female and 39 (75%) were of non Spanish origin. All but two harbored HIV-1 subtype B, being non-B variants found in the two West Africans. Exposure had been sexual in most cases, being 4 homosexual men. Seven HTLV-HIV co-infected patients had developed AIDS and two had developed myelopathy. There was no evidence for increased HTLV-1 clinical pathogenicity due to HIV coinfection. Conclusion: HIV coinfection is infrequent (< 5%) among HTLV-1 carriers in Spain. More than half of co-infected patients come from Latin America. Sexual contact is the most frequent risk behavior, being MSM one third of cases. Late diagnosis explains the high rate (9/12) of clinical manifestations in our HIV-HTLV co-infected population.

BACKGROUNDHuman immunodeficiency virus 1 (HIV-1) subtype B is predominant in Spain. However, the recent arrival of immigrant populations has increased the prevalence of non-B subtypes and circulating recombinant forms. The objective of this study was to determine the prevalence of HIV-1 subtypes and transmitted drug-resistance mutations in blood donors from the Catalonian region (northeastern Spain). STUDY DESIGN AND METHODSHIV-1-positive blood donors identified in Catalonia from 2005 to 2014 were included. Demographic variables and risk factors for HIV-1 acquisition were recorded. HIV-1 subtyping was carried out by HIV-1 DNA polymerase region sequencing, and phylogenetic analyses were performed using the neighbor-joining method. RESULTSDuring the study period, 2.8 million blood donations were screened, and 214 HIV-1-positive donors were identified, yielding an overall prevalence of 7.7 per 100,000 donations (89% men; mean age, 3410 years). Most HIV-1-positive donors were native to Spain (81%), and 61% were regular blood donors. When risk factors were known, 62% reportedly were men who had sex with men. HIV-1 subtyping was possible in 176 HIV-1-positive individuals: 143 (81%) had HIV-1 subtype B, and 33 (19%) had non-B subtypes. Most HIV-1 non-B subtypes were circulating recombinant forms (n=20; 61%). Factors associated with HIV-1 subtype B were male sex (p=0.007) and men who had sex with men (p

RCW 86 is a young supernova remnant (SNR) showing a shell-type structure at several wavelengths and is thought to be an efficient cosmic-ray (CR) accelerator. Earlier \textit{Fermi} Large Area Telescope results reported the detection of $\gamma$-ray emission coincident with the position of RCW 86 but its origin (leptonic or hadronic) remained unclear due to the poor statistics. Thanks to 6.5 years of data acquired by the \textit{Fermi}-LAT and the new event reconstruction Pass 8, we report the significant detection of spatially extended emission coming from RCW 86. The spectrum is described by a power-law function with a very hard photon index ($\Gamma = 1.42 \pm 0.1_{\rm stat} \pm 0.06_{\rm syst}$) in the 0.1--500 GeV range and an energy flux above 100 MeV of ($2.91$ $\pm$ $0.8_{\rm stat}$ $\pm$ $0.12_{\rm syst}$) $\times$ $10^{-11}$ erg cm$^{-2}$ s$^{-1}$. Gathering all the available multiwavelength (MWL) data, we perform a broadband modeling of the nonthermal emission of RCW 86 to constrain parameters of the nearby medium and bring new hints about the origin of the $\gamma$-ray emission. For the whole SNR, the modeling favors a leptonic scenario in the framework of a two-zone model with an average magnetic field of 10.2 $\pm$ 0.7 $\mu$G and a limit on the maximum energy injected into protons of 2 $\times$ 10$^{49}$ erg for a density of 1 cm$^{-3}$. In addition, parameter values are derived for the North-East (NE) and South-West (SW) regions of RCW 86, providing the first indication of a higher magnetic field in the SW region., Comment: 13 pages, 10 figures, accepted for publication in ApJ; Corresponding authors : Benjamin Condon, Marianne Lemoine-Goumard, Micaela Caragiulo

Aims: To investigate the influence of IL28B polymorphism in occult hepatitis B infection (OBI) and whether IL28B genetic variants are associated with hepatitis B virus (HBV)-specific T-cell responses. Patients and Methods: The rs12979860 IL28B genotype was determined in 34 OBI blood donors, 22 spontaneous HBV resolvers, 36 inactive HBV carriers and 25 seronegative donors. T-cell responses to HBV recombinant proteins were assessed by interferon-gamma enzyme-linked immunospot assay. Results: The frequency of the IL28B CC genotype among OBI patients was similar to that of inactive carriers [41 vs. 39%, respectively, p = 0.961; odds ratio (OR) = 1.10; 95% confidence interval (CI) = 0.42-2.86; p = 0.845]. The IL28B CC genotype was found more frequently in spontaneous resolvers, although the differences were not significant (45 vs. 39%, spontaneous resolvers and inactive carriers, respectively; p = 0.828; OR = 1.31; 95% CI = 0.45-3.83; p = 0.622). HBV-specific T-cell responses were detected in OBIs, and significantly stronger T-cell responses towards hepatitis B envelope antigen were observed in those with the IL28B CC genotype. In spontaneous resolvers and inactive carriers, IL28B CC did not correlate with the magnitude of T-cell responses. Conclusions: In OBI donors, IL28B CC correlates with the intensity of HBV-specific T-cell responses. In this study, IL28B CC is not statistically associated with OBI or with HBV clearance, but a larger number of cases is needed before completely ruling out its role in HBV infection. (C) 2015 S. Karger AG, Basel

International audience; The aim of the study was to propose a biocontrol strategy of the sycamore lace bug Corythucha ciliate (Say) combining four successive treatments of entomopathogenic nematodes (EPN) (Steinernema spp.) and the predatory insect Chrysoperla lucasina. Based on the results of former trials realized as part of the project, this strategy has been implemented in situ in six cities of different climatic regions of France. The 1st treatment with EPN on trunk, targeting overwintering adults of C. ciliate, showed a significant reduction of 60% of pest populations. The 2nd treatment with EPN enabled to reduce populations on foliage of about 50%, three weeks after application whereas the 3rd treatment, an eggs’ release of C. lucasina targeting first larval population of C. ciliate, did not show any efficacy on the whole, except on one site. Finally, the curative effect of the 4th treatment with EPN, applied at the time of the summer populations’ peak of the sycamore lace bug, could not be evaluated given that C. ciliate populations dropped drastically at this period.

Après plus de trois ans de travaux de recherche, le programme PETAAL, coordonné par le centre technique national Plante & Cité et porté par la société Koppert livre ses résultats : il propose une stratégie combinant l'utilisation de deux auxiliaires pour réguler les populations de tigre du platane.

Après plus de trois ans de travaux de recherche, le programme PETAAL, coordonné par le centre technique national Plante & Cité et porté par la société Koppert livre ses résultats : il propose une stratégie combinant l'utilisation de deux auxiliaires pour réguler les populations de tigre du platane.

Dans les vergers, la gestion satisfaisante des bioagresseurs requiert très généralement un nombre élevé de traitements phytosanitaires, en bio comme en conventionnel (Simon et al. 2011).

Date du colloque: 10/2011; International audience; Le tigre du platane,Corythuca ciliata, représente une problématique phytosanitaire majeure en espaces verts. Dans un contexte où les enjeux réglementaires et environnementaux sont favorables au développement d’outils de biocontrôle, la mise au point d’une stratégie de lutte biologique contre ce ravageur représente une innovation technique pour les professionnels. C’est l’objet du programme PETAAL (2008-2012) au cours duquel des tests en laboratoire et des expérimentationsin situdans plusieurs villes françaises ont été réalisés. Les résultats ont mis en évidence l’intérêt de nématodes entomopathogènes, pour le contrôle des populations hivernantes et estivales de tigre, et du prédateur indigèneChrysoperla lucasina,dans le contrôle des larves des populations printanières. La maîtrise des conditions d’application et le positionnement des interventions sont des facteurs clés pour garantir l’efficacité des agents biologiques. En 2011, une stratégie globale combinant les différents agents de biocontrôle a été testée en 2011 pour proposer un itinéraire technique optimal sur le plan économique et de l’efficacité.

The whitefly Bemisia tabaci Gennadius is the key pest of protected tomato production in Spain. The predominant form is biotype "Q", an efficient vector of tomato yellow leafcurl virus (TYLCV), which is the principal cause of damage. Although management has relied primarily on chemical control, factors such as overlapping crop cycles, insecticide resistance and public pressure have spurred development of alternative management tactics. These include TYLCV-tolerant varieties and pest exclusion methods that, along with more selective insecticides, have created a more compatible environment for biological control. Here we describe trials of an integrated pest management (IPM) system conducted during the fall season in 12 commercial greenhouses throughout the production area compared with 7 greenhouses utilizing only chemical control (termed "conventional"). Each IPM greenhouse was divided into 4 equal sections, two receiving weekly releases of the indigenous Eretmocerus mundus Mercet and two receiving the exotic Eretmocerus eremicus Rose & Zolnerowich. Fewer and more selective pesticides were used in IPM greenhouses compared to conventional greenhouses. Early use of broad-spectrum insecticides in IPM greenhouses appeared to be counterproductive in that establishment of parasitioids was delayed with no real gain in control. Incidence of parasitized whiteflies in IPM greenhouses averaged around 50%, with E. mundus predominating, compared to less than 3% in conve

Il existe de nombreuses serres de collection abritant parfois des espèces végétales rares. Ouvertes au publie, elles sont souvent protégées en lutte intégrée, d'où la recrudescence des cochenilles contre lesquelles peuvent être proposées des stratégies de lutte biologique; celles-ci doivent être précédées d'un inventaire aussi complet que possible des espèces en présence, cochenilles et cortège de parasitoïdes.

National audience

National audience

International audience